Novartis Settlement Encompasses Whistleblower Claims Of Kickbacks For Diovan Prescribing
This article was originally published in The Pink Sheet Daily
Executive SummaryThe company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.
You may also be interested in...
Entresto's slow market start following its US approval prompted many questions as Novartis AG reported its quarterly results Oct. 27.
Federal judge rules against Novartis’ motion to dismiss a whistleblower suit alleging violations of the anti-kickback statute and the False Claims Act, saying the government’s evidence is specific enough to proceed.
HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.